Abstract: A massager structure is provided, which includes a square plate. A top of a square plate is fixedly connected to a lower shell, and a bottom of the lower shell is fixedly connected to a motor. An output end of the motor is fixedly connected to a connection column, an outer wall of the connection column is fixedly connected to a second gear. A top of the connection column is fixedly connected to an arc-shaped massage rod, a top of the lower shell is fixedly connected to a plurality of hollow fixed rings at equidistant intervals, internals of the hollow fixed rings are connected to a fixed short rod, an outer wall of the fixed short rod is fixedly connected to a first gear, which meshes with the second gear. The arc-shaped massage rod is driven by the motor to rotate and massage a middle part of a massage area.

Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.

Abstract: Stable lyophilized therapeutic protein compositions and their methods of manufacture are provided. Specifically, the use of water as a solid cake plasticizer and protein stabilizer is described. Also, the inclusion of a multicomponent stabilizer comprising a larger molecular entity and a smaller molecular entity is described. Also, the inclusion of post-drying annealing under certain conditions improves protein stability. Proteins are predicted to remain stable over 24 months at 25° C.

Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.

Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.

Abstract: Stable lyophilized therapeutic protein compositions and their methods of manufacture are provided. Specifically, the use of water as a solid cake plasticizer and protein stabilizer is described. Also, the inclusion of a multicomponent stabilizer comprising a larger molecular entity and a smaller molecular entity is described. Also, the inclusion of post-drying annealing under certain conditions improves protein stability. Proteins are predicted to remain stable over 24 months at 25° C.

Abstract: Lyophilization methods for preparing protein formulations for long-term storage at room temperature or improved stability at refrigeration storage are provided. Specifically, the present application provides lyophilization methods to obtain a target percentage of residual moisture of a lyophilized product, such as 3-5% residual moisture. The secondary drying of the lyophilization can be conducted under controlling rate of desorption under a temperature which is similar to the shelf temperature of the primary drying. Alternatively, the lyophilization can be conducted without a distinguished secondary drying step.

Abstract: Biopharmaceutical compositions and drug products disclosed herein exhibit reduced amounts of subvisible particle formation. Compositions and drug products disclosed herein comprise a protein and a surfactant or stabilizer including high percentage amounts (e.g., at least 97%) of a long-chain fatty acid ester. Also disclosed herein are methods of preparing and storing such compositions and drug products.

Abstract: The present disclosure provides a stable protein composition containing a surfactant and having less than 400 subvisible particles of 10 microns or greater diameter per container, or less than 10,000 subvisible particles of 2 microns or greater per container. A method of manufacturing such a stable protein composition is disclosed, which includes a unit of operation that removes or decreases an esterase activity that degrades the surfactant. The unit of operation may be hydrophobic interaction chromatography or filtration, mixed mode chromatography, or the like.

Abstract: The present disclosure relates to the field of noise reduction technologies, and specifically a motor noise control method and apparatus, a computer device and a storage medium are provided. The method includes: determining a current driving mode of a vehicle and a total torque required by the vehicle in the current driving mode; acquiring an electric drive noise distribution matrix of the vehicle in the current driving mode, where the electric drive noise distribution matrix includes correspondences among target motor noises, target motor speeds, and target motor torques of respective motors in the current driving mode; and distributing a torque of each motor according to the electric drive noise distribution matrix, where a sum of torques of respective motors is equal to the total torque required by the vehicle.

Abstract: The present invention provides stable liquid pharmaceutical formulations comprising a human bispecific antibody that specifically binds to human CD20 and human CD3. In certain embodiments, the formulations contain, in addition to the bispecific antibody, a buffer, a surfactant, and a sugar. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability upon stress and storage.

Abstract: The present invention provides stable pharmaceutical formulations comprising a human antibody that specifically binds to human lymphocyte activation gene-3 (LAG-3). In certain embodiments, the formulations contain, in addition to an anti-LAG-3 antibody, a buffer, an amino acid, a non-ionic surfactant, and a sugar. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability upon stress and storage.

Abstract: The present disclosure provides a stable protein composition containing a surfactant and having less than 400 subvisible particles of 10 microns or greater diameter per container, or less than 10,000 subvisible particles of 2 microns or greater per container. A method of manufacturing such a stable protein composition is disclosed, which includes a unit of operation that removes or decreases an esterase activity that degrades the surfactant. The unit of operation may be hydrophobic interaction chromatography or filtration, mixed mode chromatography, or the like.

Abstract: Pharmaceutical formulations comprising an antibody that specifically binds to human interleukin-4 receptor alpha (hIL-4R?) are provided. The formulations may contain, in addition to an anti-IL-4R? antibody, one or more buffers, at least one amino acid, at least one sugar, and a surfactant. Methods for producing pharmaceutical formulations with reduced lipase activity are also provided, which may include subjecting a drug substance to agitation stress, heat stress, and additional ion exchange or size exclusion chromatography. In one aspect, the pharmaceutical formulations do not have appreciable subvisible particle formation in the presence of lipase, and exhibit a substantial degree of antibody stability during storage and after being subjected to thermal and other physical stresses.

Abstract: The present inventions relate to improved lyophilization methods for therapeutic proteins, such as monoclonal antibodies, using controlled nucleation. The controlled nucleation approach is time efficient, and produces lyophilized products with high quality and faster reconstitution times. The present inventions also relate to efficient lyophilization process to achieve moderate moisture content in room temperature stable therapeutic proteins.

Abstract: The present disclosure relates to the field of noise reduction technologies, and specifically a motor noise control method and apparatus, a computer device and a storage medium are provided. The method includes: determining a current driving mode of a vehicle and a total torque required by the vehicle in the current driving mode; acquiring an electric drive noise distribution matrix of the vehicle in the current driving mode, where the electric drive noise distribution matrix includes correspondences among target motor noises, target motor speeds, and target motor torques of respective motors in the current driving mode; and distributing a torque of each motor according to the electric drive noise distribution matrix, where a sum of torques of the respective motors is equal to the total torque required by the vehicle.

Abstract: The present disclosure provides a stable protein composition containing a surfactant and having less than 400 subvisible particles of 10 microns or greater diameter per container, or less than 10,000 subvisible particles of 2 microns or greater per container. A method of manufacturing such a stable protein composition is disclosed, which includes a unit of operation that removes or decreases an esterase activity that degrades the surfactant. The unit of operation may be hydrophobic interaction chromatography or filtration, mixed mode chromatography, or the like.

Abstract: Lyophilization methods for preparing protein formulations for long-term storage at room temperature or improved stability at refrigeration storage are provided. Specifically, the present application provides lyophilization methods to obtain a target percentage of residual moisture of a lyophilized product, such as 3-5% residual moisture. The secondary drying of the lyophilization can be conducted under controlling rate of desorption under a temperature which is similar to the shelf temperature of the primary drying. Alternatively, the lyophilization can be conducted without a distinguished secondary drying step.

Abstract: Methods for stabilizing an Fc-containing protein preparation in an aqueous solution are provided herein. The disclosed methods can stabilize the Fc-containing protein in a drug product, especially for liquid formulations, by using phenol or benzyl alcohol as preservatives.

Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.